| abstract |
Composition comprising a GLP-1 molecule selected from among GLP-1 (1-37) (SEQ ID NO: 1), GLP-1 (1-36) NH2 (SEQ ID NO: 2), GLP -1 (7-37) (SEQ ID NO: 3), GLP-1 (7-36) NH2 (SEQ ID NO: 4), exendina-3 (SEQ ID NO: 7), exendina -4 (SEQ ID NO: 9) or a biologically active variant that has more than 90% sequence identity with any of SEQ ID 1 to 4, for use in the treatment of a patient suffering from ovarian polycystosis (PCOS ) - in which the patient has at least one indicative symptom of PCOS selected from the group comprising insulin resistance, hyperinsulinemia, hypertension, hyperlipidemia, anovulation or irregular ovulation, sterility, hyperandrogenism, hirsutism, alopecia, acne, hypertrophy of the multifollicular ovaries, changes in metrorrhagia and spontaneous abortions. |